- Home
- Advocacy
- Latest News and Practice Data
- Latest Updates on LDT Oversight
The Senate returned to Congress to consider a number of bills, but a vote on legislation to reauthorize existing Food & Drug Administration (FDA) user fees and the VALID Act is uncertain. The FDA needs funding from user fees, which must be reauthorized by Congress, to support its programs. FDA Commissioner Robert Califf, MD, has said recently that the FDA has enough funds to last until November – which would buy Congress additional time to find a compromise.
On July 20, the CAP, American Society of Clinical Oncology (ASCO), American Cancer Society Cancer Action Network, and several patient, laboratory industry, and other advocacy groups urged Congress to enact the VALID Act as part of the FDA user fee bill.
Additional resources and information are available from the CAP: